We have completed a third-party allotment of capital. While aiming to increase the number of N-NOSE tests and improve the consultation rate, we will promote our business with the immediate goal of putting the next-generation cancer type specific tests into practical use.
On March 18, 2024, an reveiw articles on cancer screening by a third-party research team (Romania) was published in "Cancers", an oncology journ . . .
2024.03.29HIROTSU Bioscience Inc. (Head Office: Chiyoda-ku, Tokyo, Representative: Takaaki Hirotsu, hereinafter referred to as “HIROTSU) has verified the . . .
2024.02.29HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative Director: Takaaki Hirotsu; hereinafter referred to as "HIROTSU") has su . . .
2024.02.20